Navigation Links
Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave(R) (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the American Diabetes Association (ADA) 69th Scientific Sessions, June 5-9, 2009, and the 91st Annual Meeting of the Endocrine Society (ENDO), June 10-13, 2009.

ADA: Ernest N. Morial Convention Center, New Orleans, LA.

    Saturday, June 6:  Embargo Lifts June 6 at 9:00 a.m. CT
    Oral Presentation
    Abstract: 37-OR
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, PA
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss:
    A 56-week Phase 3 Study"
    Time: 9:00 a.m. CT
    Location: Room 255

    Monday, June 8:  Embargo Lifts June 6 at 10:00 a.m. CT
    Poster Presentation*
    Abstract: 1731-P
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, Pa.
    Title: "Naltrexone + Bupropion Combination Causes Weight Loss and Improves
    Quality of Life"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    Poster Presentation*
    Abstract: 1730-P
    Presenter: Samuel Klein, M.D., Washington University School of Medicine,
    St. Louis, Mo.
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss
    Without Worsening Psychiatric Symptoms"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    * Posters will also be presented Sunday, June 7 from 6:30 - 7:45 p.m. CT
    at a Poster Reception in Hall E

ENDO: Walter E. Washington Convention Center, Washington,
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)...  ( www.competitivehealth.com ) — Competitive Health is pleased ... and advocacy service, has signed an agreement to become ... health services marketplace. 63% of Americans have ... expected to pay. As part of an ongoing effort ... is pleased to offer medical bill review and negotiation ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.519 12/2001 , , ... , , , Microorganism , ... Cell type , Bacteria, gram positive, ...
... / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.516 12/2001 , , , , ... , Microorganism , Kluyveromyces lactis ... type , Yeast, , , ...
... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. 4308 915.509 ... , , , , , , ... , Cell type , ...
Cached Biology Technology:Lactococcus lactis 2Kluyveromyces lactis 2Clostridium botulinum 2
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... trial led by a researcher at the University of ... a new approach to treat triple-negative breast cancer, an ... African-Americans and young women. The study will help researchers ... cells to express a protein called an estrogen receptor ...
... lead the first international, multidisciplinary assessment of the levels ... off the Fukushima nuclear power planta research effort funded ... "This project will address fundamental questions about the ... and in the process enhance international collaboration and sharing ...
... PHILADELPHIA (June 2, 2011) -- Although bitterness can sometimes ... or chocolate more often bitter taste causes rejection that ... is especially true for children. Now, scientists from the Monell ... that inhibits bitterness by acting directly on a subset of ...
Cached Biology News:New clinical trial to test novel approach to treat triple-negative breast cancer 2New clinical trial to test novel approach to treat triple-negative breast cancer 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 2Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 4Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 5New bitter blocker discovered 2
Polymerase (RNA) II (DNA directed) polypeptide L...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... of ICE-family proteases/caspases initiates apoptosis in mammalian ... Detection Kit provides a simple and convenient ... flow cytometry in intact cells. The ... aspartate residues linked to rhodamine 110 (D2R), ...
Biology Products: